IND Submission by Synergy Pharma - Analyst Blog

Shutterstock photo

Synergy Pharmaceuticals Inc. ( SGYP ) recently announced the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for its inflammatory bowel disease (IBD) candidate, SP-333.

SP-333, a second generation guanylyl cyclase C (GC-C) receptor agonist, has the potential to be developed for the treatment of gastrointestinal (GI) inflammatory disorders and diseases.

Synergy Pharma is looking to initiate a phase I study with the candidate later this year. The study is expected to enroll more than 300 patients at 40 sites in the US.

In pre-clinical studies, 0.05 mg/kg body weight dosage of SP-333 demonstrated superior anti-inflammatory activity when compared to 100mg/kg dosages of 5-aminosalicylic acid (5-ASA).

Synergy Pharma primarily develops drugs for the treatment of GI disorders and diseases. The company's lead candidate, plecanatide, is being developed for GI disorders.

The company is developing plecanatide for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). The company plans to initiate the first trial in IBS-C patients later this year.

We note currently approved drugs for the treatment of GI inflammatory disease include Pfizer Inc. 's ( PFE ) Dipentum, AstraZeneca 's ( AZN ) Entocort and Salix Pharmaceuticals, Ltd. 's ( SLXP ) Colazal.

Synergy Pharma was in the news recently due to the acquisition of all assets related to FV-100, an oral nucleoside analogue, from Bristol-Myers Squibb Company ( BMY ), developed to treat shingles, a severe painful skin rash caused by the varicella zoster virus (the same virus that causes chickenpox).

Our Recommendation

We currently have a Neutral recommendation on Synergy Pharma. However, the stock carries a Zacks #4 Rank (Sell rating) in the short run.

ASTRAZENECA PLC (AZN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
SYNERGY PHARMAC (SGYP): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
Referenced Symbols: AZN , BMY , IND , PFE , SGYP

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by